TL;DR
This paper outlines a rigorous, multi-center, randomized controlled trial protocol to investigate the efficacy of three Traditional Chinese Medicine (TCM) prescriptions for treating ischemic stroke (IS) patients with a specific syndrome (Qi Deficiency and Blood Stasis). The study aims to not only evaluate clinical outcomes but also identify objective biomarkers to better understand the "prescription-syndrome correlation" (PSC) and pave the way for more precise TCM treatments.
What Problem Does This Paper Address?
Ischemic stroke (IS) is a leading cause of death and disability worldwide. While Western medicine plays a crucial role, Traditional Chinese Medicine (TCM) offers a complementary approach that has shown promise in improving recovery and quality of life for IS patients. A common TCM diagnosis for IS is "Qi Deficiency and Blood Stasis" (QDBS), for which the principle of "invigorating Qi and activating blood circulation" is applied. However, a key challenge in TCM is the subjective nature of syndrome diagnosis and the difficulty in objectively quantifying the effectiveness of prescriptions in relation to these syndromes. This "prescription-syndrome correlation" (PSC) is crucial for optimizing treatment, but lacks objective validation. This study aims to bridge this gap by evaluating specific TCM prescriptions for QDBS syndrome and identifying objective biomarkers that can serve as a basis for precise TCM treatment.
Methods
The study employs a multicenter, randomized, double-blinded, placebo-controlled trial design. 160 IS patients diagnosed with QDBS syndrome will be recruited from seven hospitals in China. Participants will be randomly assigned to one of four groups in a 1:2:1:1 ratio:
- Experimental Group 1: Buyang Huanwu granules (BHG)
- Experimental Group 2: Naoxintong capsules (NXTC)
- Experimental Group 3: Yangyin Tongnao granules (YTG)
- Placebo Control Group
All participants will receive standard Western medical care for IS. The intervention period will be 28 days, followed by a 180-day follow-up period.
Key methodological aspects include: * Double-blind, double-simulation design: To minimize bias, both the active drugs and placebo will be designed to look, taste, and feel identical. * Objective and Subjective Outcome Measures: * Primary Outcome: Change in the National Institutes of Health Stroke Scale (NIHSS) score after 28 days. * Secondary Outcomes: Modified Rankin Scale (mRS) score, Activity of Daily Living (ADL) scale (Barthel Index), and TCM symptom scores. * Biomarker Exploration: A subset of patients will undergo extensive blood and urine sample analysis using advanced techniques like proteomics, metabolomics, and analysis of specific biological indicators (e.g., inflammatory markers, coagulation factors) to identify potential biomarkers related to PSC. * Rigorous Ethical and Regulatory Compliance: The study adheres to the Declaration of Helsinki, ICH-GCP guidelines, and is registered with the Chinese Clinical Trial Registry.
Datasets
Not discussed in the paper. The study focuses on patient recruitment and data collection from participants.
Key Insights and Ideas
- Bridging Subjectivity and Objectivity in TCM: The core idea is to move beyond subjective symptom assessment in TCM by integrating objective clinical measures and novel biomarker discovery. This is crucial for advancing TCM's acceptance and integration into modern healthcare.
- The Importance of Prescription-Syndrome Correlation (PSC): The study highlights that simply using a prescription isn't enough; understanding how well it matches the specific syndrome (PSC) is key to maximizing efficacy. This trial aims to quantify this correlation.
- Multi-modal Approach to Stroke Treatment: The study acknowledges the value of integrating TCM with Western medicine, proposing an "add-on" approach to enhance treatment outcomes.
- Biomarker Discovery for Precision Medicine: By exploring proteomics and metabolomics, the study aims to uncover the underlying biological mechanisms of these TCM prescriptions, paving the way for personalized TCM treatments.
Key Results
As this is a study protocol, no results are presented yet. The paper details the planned methodology for data collection and analysis.
Limitations and Future Work
- Limited Treatment Duration: The authors acknowledge that the 28-day treatment period is relatively short. They suggest that future RCTs should include longer follow-up periods to assess the long-term effects of the prescriptions.
- Uncertainty of Long-Term Outcomes: The study protocol does not explicitly detail the assessment of long-term outcomes like mortality or major vascular events, which are crucial for stroke management. Future research should address this.
- Potential for Confounding Factors: While efforts are made to control for confounding variables, the complexity of IS and its treatment means that unforeseen factors could influence results.
- Future Work: The authors propose that future research should focus on longer follow-up periods and potentially explore the role of these prescriptions in reducing overall mortality and major vascular events. The identification of biomarkers is also a key step towards developing more precise and personalized TCM treatments.
Summary updated